At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- CIT-013 high dose (drug), CIT-013 medium dose (drug), Placebo (drug)
- How long the study runs
- Study runs about 21 months (dates as stated)
- About the drug or intervention
- CIT-013 high dose — drug: subcutaneous injection · CIT-013 medium dose — drug: subcutaneous injection · Placebo — drug: subcutaneous injection
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a medicine called CIT-013 in people with hidradenitis suppurativa (HS), a long-term skin condition that causes painful lumps and abscesses. The study is being run by Citryll BV.
Who can take part
- Adults aged 18 or over
- Have had HS for more than 6 months
- Have HS sores in at least 2 separate areas of the body, with at least one area at Hurley Stage II or III (a way of measuring how severe HS is)
- Have at least 5 abscesses or inflamed lumps at screening and on Day 1
- Have not responded well enough to antibiotic tablets, or the HS came back after stopping them, or the antibiotics caused problems or cannot be used
- Have fewer than 20 draining tunnels (tunnels under the skin that leak fluid)
Who may not be able to
- People who could use and tolerate an approved treatment that is known to help, or who choose standard care instead
- Have another significant skin condition in the area being treated
- Have had a treatment made from recombinant proteins (a lab-made type of medicine) in the 6 weeks before the start
- Have had other HS treatments taken by mouth or injection into the bloodstream in the weeks before the start (28 days for HS tablets, 14 days for intravenous anti-infection medicines)
- Have had cancer, apart from non-melanoma skin cancer that has been removed and cured
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 96
- Started
- 2025-10-31
- Last checked
- 2025-11
Plain English Summary
What is this study?
- • Testing a new treatment for hidradenitis suppurativa (hs)
- • Phase2 - 96 participants
- • The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with hidradenitis suppurativa (hs)
Where?
- • Cardiff - GB-02
- • Chester - GB-05
- • London - GB-04
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Male or female participants with HS of more than 6 months duration,
- ✓18 years of age at screening visit,
- ✓Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III...
- ✓A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment/randomization,
- ✓Total draining tunnel count less than 20
Who cannot take part
- ✗Any current and/or recurrent clinically significant skin condition in the treatment area other than HS,
- ✗Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline
- ✗Prior treatment with any of the following medications before baseline:
- ✗Any other treatment that goes through your whole body for HS (28 days before baseline)
- ✗Any IV anti-infective therapy (14 days before baseline)
See the full criteria
Where Is This Study? (3 UK sites)
GB-02
Cardiff, United Kingdom
GB-05
Chester, United Kingdom
GB-04
London, United Kingdom
How to Get in Touch
Leonie M Middelink
Sponsor contactCONTACT